Lawyers Pursue Skin Cancer Cases After Medication Use
(NewsUSA)
- The anti-inflammatory medication dupilumab, marketed as Dupixent, is the subject of a lawsuit alleging a link between the use of the medication and the development of a type of skin cancer known as cutaneous T-cell lymphoma (CTCL).
Dupixent is prescribed for several medical conditions including asthma and eczema. CTCL is a type of skin cancer that develops in white blood cells, which help the body fight infection.
Early signs and symptoms of CTCL include red, scaly patches, rashes, lumps and bumps, discoloration, thickened skin, swollen lymph nodes, hair loss, itching, fever and chills, unexplained weight loss, pain or tenderness, and night sweats. As CTCL progresses, the visual changes can affect up to 80% of the skin’s surface. Ultimately, the disease can spread to internal organs, including the spleen and liver.
Dupixent manufacturers Regeneron Pharmaceuticals and Sanofi Genzyme failed to adequately warn of the risks in taking the drug, according to Ellen Relkin, partner in the law firm of Weitz & Luxenberg and practice group chair of the firm’s Drug and Medical Device Litigation team. The law firm of Weitz & Luxenberg is taking legal cases for patients who have and used an anti-inflammatory medication and have been diagnosed with skin cancer.
“Cutaneous T-cell lymphoma is a very rare type of skin cancer. This makes it all the more critical for the manufacturer to warn patients about the danger,” states Relkin.
A study in the Journal of the American Academy of Dermatology reported an increased risk of CTCL was found in a cohort of atopic dermatitis patients who used dupilumab. “The increased risk persisted after exclusion of prior disease-modifying antirheumatic drug use. Risk was not increased for other cutaneous or lymphoid malignancies,” the researchers wrote.
“Doctors and patients alike need to be sufficiently warned, and patients who take Dupixent, and their doctors, need to keep a careful eye out for any disturbing changes to their skin,” says Ms. Relkin.
“Those who took Dupixent and are suffering deserve compensation. And we are going to help you get it,” she insists.
Weitz & Luxenberg is encouraging anyone diagnosed with CTCL who used Dupixent to contact the firm for information about legal options and a free initial consultation. Call (917) LAWYERS or visit https://www.weitzlux.com/firm-news/dupixent-skin-cancer-lawsuit-ctcl/.
- The end of summer means back-to-school season for families across the country. As parents shop for new backpacks and clothes, they should be sure not to overlook one of the most important parts of the back-to-school checklist – the visual health of their child.
- In a virtual café, students write resumes, sit for interviews, and take on roles that imitate real-world jobs. In an RV-turned-lab, a health science teacher travels across her state, helping students earn professional certificates. In Colorado, others climb a 13,000-foot mountain while taking steps to earn a wilderness first aid certification. And in Tokyo, a young inventor confidently presents his creation—an AI-powered tool for early cancer detection.
- For millions of children across America, the back-to-school season is filled with excitement and promise. But for far too many, it begins without access to books—the most critical tool for academic success. Every student deserves to walk into school embraced by the excitement of learning—not burdened by what they lack. Marine Toys for Tots—the Nation’s premier Christmastime children’s charity—has grown into a powerful, year-round force for good. Among its year-round programs, the Toys for Tots Literacy Program continues to provide pages of possibility and ignite a love of reading to disadvantaged children well beyond the holiday season through Operation Turn the Page.
- The passage into law of the One Big Beautiful Bill Act marks a substantial shift in U.S. energy policy — reversing policies that have powered energy growth to meet skyrocketing energy demand. While proponents cast it as a pro-growth, budget‑cutting measure, its impact on America’s burgeoning solar, wind, and storage industries is profoundly concerning.
- Millions Are Affected by NTM Lung Disease Each Year—Experts Call for Earlier Detection, Research, and Patient Support
NTM lung disease is caused by environmental bacteria found in water and soil. While many are exposed, people with underlying lung conditions—particularly bronchiectasis—are at higher risk of infection. Alarmingly, new data show that NTM cases are rising by more than 8.2% annually, particularly among women over age 65 and individuals with chronic lung disease. The economic burden per patient can exceed $30,000 per year, underscoring the cost of delayed diagnosis and limited treatment options.
- Summer is the season to celebrate citrus—bright, juicy, and bursting with flavor. Right now, fresh lemons, mandarins, and navel oranges from Chile are arriving in stores, bringing a taste of sunshine from the Southern Hemisphere straight to your table. Each fruit offers unique health benefits and endless ways to enjoy them in the warm months ahead.
- News - the good, the bad, the fake - is everywhere, all the time. It’s on our phones, feeds and in our faces 24/7. And while that can be overwhelming for adults, it’s downright distressing for children who haven’t yet developed the skills to look beyond scary headlines, clickbait, and partisan spin.
-
“A Magical Loveliness of Ladybugs” by Amy L. Stark, Ph.D.
“The Bitter End Birding Society” by Amanda Cox
“Anchored by Love” by Marie-Claire Moriah Wright and David Saccoh Wright
“Design for Your Mind” by Annie Guest
- By Matt Werbach for the National Psoriasis Foundation 
